| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1447d10c00d46fd3863869d42e33df44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_955deaec776415c904d92144c286ec46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed8b5c72be18a88c9a5a58cd2aec7698
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a4483694d3dc2df997540aff58515b60 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 |
| filingDate |
2014-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_169507e0ec29ca1a64f2985800618f0c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddd9bd0e7f94c114158832adee2828be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8bdc0d47e015807361dd7954c0c467d |
| publicationDate |
2014-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2014186423-A1 |
| titleOfInvention |
Combination therapy for treating hiv and aids |
| abstract |
The present invention relates to the use of a Vif inhibitor and an APOBEC3G (A3G) activator in combination to inhibit HIV infectivity in a host cell and to treat or prevent HIV infection or AIDS in a patient. In one embodiment, the present invention relates to a method for inhibiting infectivity of HIV in a host cell, which method comprises contacting a host cell comprising A3G host defense factor with a combination of antiviral-effective amounts of a Vif inhibitor and an A3G activator, thereby inhibiting infectivity of HIV in the host cell by simultaneously inhibiting Vif-dependent degradation of A3G and activating A3G deaminase activity in the host cell, where the Vif inhibitor inhibits Vif-dependent degradation of A3G by disrupting or inhibiting dimerization of Vif in the host cell, and where the A3G activator activates A3G deaminase activity by disrupting or inhibiting A3G:nucleic acid molecule interaction in the host cell. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11116762-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10588902-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018128993-A1 |
| priorityDate |
2013-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |